Study on apo A-IV polymorphism in patients with hyperlipidemia.

高脂血症患者apo A-IV多态性研究

• 批准号: 07672485
• 负责人: SEISHIMA Mitsuru
• 金额: $ 1.22万
• 依托单位: Gifu University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1995
• 资助国家: 日本
• 起止时间: 1995 至 1996
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-07672485/
• 关键词: Apo A-IV; Polymorphism; Hyperlipidemia

We compared the frequencies of apo A-IV polymorphism at codon 347 and 360 in 40 hyperlipidemic patients with 131 healthy controls. All healthy controls and hyperlipidemic patients studied here had Thr/Thr at codon 347. This result was different with a report in Western, which showed the frequency of Ser allele was 0.144 to 0.216. On the other hand, the frequency of Gln/llis at codon 360 in hyperlipidemic patients was 17.5%, which was lower than 22% in controls although there was no statistical difference between them. It is well known that Gln/Gln and His/His at codon 360 are corresponded to A-IV-1 and A-IV-2, respectively at protein level. It has been reported that subjects with A-IV-2 show higher HDL-C and LCAT activity compared to those with A-IV-1.In addition, A-IV-2 regulates cholesterol absorbtion in the small intestine. These isoforms, thus, have different functions in the lipid metabolism. In view of this point, few frequency of Gln/His (A-IV-2) in hyperlipidemic patients may indicate that this varient is associated with the cause for hyperlipidemia. However, in the present study, we could not find the difference in the frequency of apo A-IV polymorphism among subtypes of hyperlipidemia, but further study will be necessary in large scale of number.

我们比较了 40 名高脂血症患者和 131 名健康对照者的 apo A-IV 密码子 347 和 360 多态性频率。这里研究的所有健康对照和高脂血症患者在密码子347处都有Thr/Thr。这个结果与Western的报告不同，该报告显示Ser等位基因的频率为0.144至0.216。另一方面，高脂血症患者中密码子360处的Gln/llis频率为17.5%，低于对照组的22%，但两者之间没有统计学差异。众所周知，密码子360处的Gln/Gln和His/His在蛋白质水平上分别对应于A-IV-1和A-IV-2。据报道，与 A-IV-1 受试者相比，A-IV-2 受试者表现出更高的 HDL-C 和 LCAT 活性。此外，A-IV-2 调节小肠中的胆固醇吸收。因此，这些亚型在脂质代谢中具有不同的功能。鉴于这一点，高脂血症患者中Gln/His（A-IV-2）的很少出现频率可能表明该变异与高脂血症的病因有关。但在本研究中，我们未能发现高脂血症亚型之间apo A-IV多态性频率的差异，还需要进一步的大规模研究。

项目成果

Seishima, M. et al.: "Reduced intestinal apo A-IV mRNA levels in patienta with liver cirrhosis" Int. Hepatol. Commun.4. 153-159 (1995)

Seishima, M. 等人：“肝硬化患者肠道 apo A-IV mRNA 水平降低”Int。

Nishimura, M.et al.: "Effects of lipid administration on lymphatic apolipoprotein A-IV and B output and synthesis" Am.J.Physiol.271. 322-329 (1996)

Nishimura, M.等人：“脂质给药对淋巴载脂蛋白 A-IV 和 B 输出和合成的影响”Am.J.Physiol.271。

Seishima, M.et al.: "Reduction of intestinal apo A-IV mRNA levels in the cirrhoticrat" J.Hepatol.Gastroenterol.11. 746-751 (1996)

Seishima, M.et al.：“肝硬化大鼠肠道 apo A-IV mRNA 水平的降低”J.Hepatol.Gastroenterol.11。

Seishima, M. et al.: "Reduction of intestinal apo A-IV mRNA levels in the cirrhotic rat" J. Hepatol. Gastroenterol.11. 746-751 (1996)

Seishima, M. 等人：“肝硬化大鼠肠道 apo A-IV mRNA 水平的降低”J. Hepatol。

Seishima, M.et al.: "Reduced intestinal apo A-IV mRNA levels in patients with liver cirrhosis" Int.Hepatol.Commun. 4. 153-159 (1995)

Seishima, M.et al.：“肝硬化患者肠道 apo A-IV mRNA 水平降低”Int.Hepatol.Commun。